UK +44 (0)1223 491486      USA toll free 1-866 877 2185

Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

Qkine certified ISO9001: 2015 for its quality management system encompassing R&D, manufacturing, and operations in Cambridge, UK. Qkine supplies growth factors and cytokines to the fast-moving stem cell, organoid and emerging cultured meat sectors. Exceptional product quality and scientific support are crucial to customer's business processes and experimental outcomes.

By |2021-09-10T18:53:50+00:00September 10th, 2021|awards, cellular agriculture, news, press release, quality|Comments Off on Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

By |2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, news, press release, protein engineering, protein science, stem cells|Comments Off on Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

pep talk June 2021

June update with featured publication from Austin Smith lab, Kinoshita et al - capture of mouse and human stem cells with features of formative pluripotency; introduction to our "class of 2021" new products we've made this year; explaining pioneering proteins that bring innovative growth factors to stem cell researchers and free reconstitution solution to make lab life easy

By |2021-07-12T21:27:26+00:00June 10th, 2021|news, resources, stem cells|Comments Off on pep talk June 2021

pioneering proteins launch

We are proud to launch our Pioneering Protein range! A range of modified proteins have been carefully developed by world leading academic laboratories, licenced through Cambridge Enterprise, and then manufactured to our high purity and bioactivity standards, bringing together academic innovation with high level manufacturing purity. Folloistatin-resistant activin A (FRACTA) has been developed by our [...]

By |2021-03-12T13:00:44+00:00March 10th, 2021|news, protein engineering, protein science|Comments Off on pioneering proteins launch

Celebrating International Women’s Day 2021 with our amazing team, collaborators, customers and wider network

At Qkine we are so proud of all the wonderful women we work with! This #InternationalWomensDay we want to celebrate our amazing network and empower #WomenInSTEM to learn from and help each other #empoweringwomen #womenpower

By |2021-03-10T14:20:30+00:00March 8th, 2021|news|Comments Off on Celebrating International Women’s Day 2021 with our amazing team, collaborators, customers and wider network

Catherine Elton, Qkine founder and CEO, recognised in the #21towatch in 2021

The #21toWatch campaign showcases 7 people, 7 companies and 7 inventions at the forefront of innovation in Cambridge and the East of England. The results were announced on the 4th March and we are delighted that our CEO, Catherine Elton, was named one of the 7 “people” to watch.

By |2021-03-08T17:47:55+00:00March 8th, 2021|awards, news|Comments Off on Catherine Elton, Qkine founder and CEO, recognised in the #21towatch in 2021

Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

Qkine, Manchester BIOGEL and Cellesce have been awarded Innovate UK Sustainable Innovation Funding to develop fully synthetic, chemically-defined three-dimensional (3D) scaffolds to enable manufacture scale up and improve reproducibility of patient-derived organoids.

By |2020-11-25T15:00:51+00:00November 25th, 2020|animal-free, news, organoid news|Comments Off on Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

Qkine shortlisted in the Cambridge Independent 2020 Science & Technology awards

Qkine is delighted to have been shortlisted in the prestigious Cambridge Independent 2020 Science and Technology Awards. Sponsored by Kao Data, the Startup of the Year shortlist recognises "early-stage companies that show entrepreneurial drive to solve a problem, or improve on what is already out there". Qkine would like to extend its congratulations [...]

By |2020-11-11T12:05:36+00:00November 11th, 2020|awards, news|Comments Off on Qkine shortlisted in the Cambridge Independent 2020 Science & Technology awards

Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]

By |2020-12-08T16:06:23+00:00July 21st, 2020|news, press release|Comments Off on Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

Qkine secures £1.5M series A funding from leading life science investors

Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global scale-up of its commercial operations and make key hires to its leadership team. The funding [...]

By |2020-12-08T16:09:36+00:00June 8th, 2020|news, press release|Comments Off on Qkine secures £1.5M series A funding from leading life science investors

Go to Top